Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation

References

• Xu-Monette ZY, Young KH. Therapeutic vaccines for aggressive B-cell lymphoma. Leuk Lymphoma. 2020;61(13):3038–3051.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32.
   PubMed Web of Science ®Google Scholar
• Cherng HJ, Westin J. Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2021;62(6):1302–1312.
   PubMed Web of Science ®Google Scholar
• Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87.
   PubMed Web of Science ®Google Scholar
• Jain P, Fayad LE, Rosenwald A, et al. Recent advances in de novo CD5+ diffuse large B cell lymphoma. Am J Hematol. 2013;88(9):798–802.
   PubMed Web of Science ®Google Scholar
• Alinari L, Gru A, Quinion C, et al. De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016;91(4):395–399.
   PubMed Web of Science ®Google Scholar
• Durani U, Ansell SM. CD5+ diffuse large B-cell lymphoma: a narrative review. Leuk Lymphoma. 2021;62(13):3078–3086.
   Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Oka K, Hiasa A, et al. De novo CD5 + diffuse large B-cell lymphomas express VH genes with somatic mutation. Blood. 1998;91(4):1145–1151.
   PubMed Web of Science ®Google Scholar
• Burgueño Bucio E, Mier Aguilar CA, Soldevila G. The multiple faces of CD5. J Leukoc Biol. 2019;105(5):891–904.
   PubMed Web of Science ®Google Scholar
• Mageed RA, Garaud S, Taher TE, et al. CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte. Autoimmun Rev. 2012;11(11):795–798.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohno T, Oka K, et al. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol. 1999;105(4):1133–1139.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99(3):815–821.
   PubMed Web of Science ®Google Scholar
• Chuang W, Chang H, Shih L, et al. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. Virchows Arch. 2015;467(5):571–582.
   PubMed Web of Science ®Google Scholar
• Lamy T, Damaj G, Soubeyran P, LYSA Group, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174–181.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008;19(11):1921–1926.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Novo M. Bcl-2 inhibition in DLBCL: "the times they are a-changing"? Blood. 2021;137(5):577–579.
   PubMed Web of Science ®Google Scholar
• Bolen CR, Klanova M, Trneny M, et al. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. Haematologica. 2020;105(9):2298–2307.
   PubMed Web of Science ®Google Scholar
• Vargo JA, Gill BS, Balasubramani GK, et al. Treatment selection and survival outcomes in early-stage diffuse large B-Cell lymphoma: do We still need consolidative radiotherapy? J Clin Oncol. 2015;33(32):3710–3717.
   PubMed Web of Science ®Google Scholar
• Longo DL. Combined-Modality therapy for early-stage diffuse large B-cell lymphoma: knowing when to quit. J Clin Oncol. 2015;33(32):3684–3685.
   PubMed Web of Science ®Google Scholar
• Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the groupe d’Etude des lymphomes de l’Adulte. J Clin Oncol. 2007;25(7):787–792.
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352(12):1197–1205.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol. 2004;22(15):3032–3038.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Yamaguchi M, Suzuki R, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22(7):1601–1607.
   PubMed Web of Science ®Google Scholar
• Garcia-Suarez J, Banas H, Arribas I, et al. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. Br J Haematol. 2007;136(2):276–285.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Asano N, Yamada T, et al. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. Haematologica. 2020;105(9):2308–2315.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Eyre TA, Martinez-Calle N, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. Blood Advances. 2020;4(15):3586–3593.
   PubMed Web of Science ®Google Scholar
• Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–1029.
   PubMed Web of Science ®Google Scholar
• Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019;133(5):436–445.
   PubMed Web of Science ®Google Scholar
• Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)† ). Ann Oncol. 2019;30(4):621–628.
   PubMed Web of Science ®Google Scholar